Zafgen to scrap lead obesity drug, shares slide - Reuters

STAT

Zafgen to scrap lead obesity drug, shares slide Reuters Zafgen Inc said it was suspending the development of its lead obesity drug, beloranib, more than six months after the U.S. Food and Drug Administration asked the company to halt all tests on the drug following the death of two patients. Zafgen's shares ... Boston's Zafgen cuts jobs, shifts focus on obesity drugsThe Boston Globe Zafgen ditches lead candidate after deaths, aims for clinic in 1Q17FierceBiotech Zafgen Restructures, Abandons Obesity Drug Following FDA MeetingXconomy Seeking Alpha -StreetInsider.com -MarketWatch -STAT all 11 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGUOU3cGWrvSyXRylHj7j6EADx9ow&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779163492686&ei=OdiOV4iJCs2j3wGqgYOoAQ&url=http://in.reuters.com/article/us-zafgen-study-idINKCN0ZZ2PT
via IFTTT